Molecule to Market: Inside the outsourcing space

The big pharma sourcing specialist

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Daniel Hogan, External Manufacturing Team Lead for the Americas at Bayer Pharmaceuticals.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Daniel, covering:

• Managing a portfolio of 30-50 CMO partners across OSD, aerosols, topicals and liquids. And why due diligence and careful CMO selection is vital given its 10 x harder to exit a site.
• Some of the fundamental differences and similarities between sourcing as a big pharma and a small biotech.
• What good and bad relationships look like with an outsourced partner.
• The proliferation and availability of vendors in the outsourcing space. And why there is always room for CDMOs/CMOs with novel capabilities.
• Timeless advice for CDMOs/CMOs/CPOs in building relationships and revenue with big pharma.

With almost 20 years in the sector, Dan’s technical knowledge encompasses diverse pharmaceutical dosage forms with experience manufacturing and formulating a wide range of products for oral, topical, and parenteral administration. He thrives on contributing to complex products with the potential to cure people of disease, enabling them to lead lives of health and wellness.

Leading a team of experienced engineers responsible for the technology interface between Bayer and Contract Manufacturing Organizations (CMOs), Dan currently manages the manufacturing of a diverse dosage, multimillion-dollar product portfolio while providing guidance on activities such as process optimization, technology transfer from Bayer research and development to CMOs and validation of processes at commercial scale at various CMOs.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

We are also proudly supported by Zymewire, which is the leader in actionable sales intelligence for life science Business development professionals. In fact, thousands of life science BD professionals start their day with sales signals from Zymewire. Learn more at - zymewire.com

 

The Cleanroom Veteran

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Grant Merrill President & CEO at AES Clean Technology.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Grant, covering:

• Becoming the leader of the business that he dreamt of representing.
• The need for cleanrooms to work in an invisible way as the most critical square footage at the core of the facility.
• Having to keep up with demand during the pandemic with the swelling production needed due to covid vaccines.
• The new therapeutic areas that are driving market growth and the need to let science flourish.
• Why the CMO space is poised for growth in both drug substance and drug product.
• The simple but magical abilities of being able to communicate and building personal relationships.

Grant Merrill has been involved with cleanroom design and construction for over 25 years. He earned his BS in Mechanical Engineering from Cornell University, and then immediately entered the world of critical facilities and the mechanical systems that support them. After a successful career in the industrial HVAC engineering business, Grant joined the AES team 20 years ago. Now as President & CEO, he leads multi-disciplinary teams to deliver complex cleanroom facilities to clients throughout the life science industry.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed. 

We are also proudly supported by Zymewire, which is the leader in actionable sales intelligence for life science Business development professionals. In fact, thousands of life science BD professionals start their day with sales signals from Zymewire. Learn more at - zymewire.com

The 4Cs every CDMO vendor should know

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Carl Turner, Vice President Supply Chain at Mayne Pharma.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Carl, covering:

• Managing 30+ CDMOs across several drug delivery systems and having the unique perspective of being on the buy CMO side, but having visibility of the CMO sell side.
• The 4 Cs that Carl looks for in sourcing, evaluating and selecting a new CMO partner. And what a great vendor relationship looks like
• The constant balancing act of risk mitigation and achieving economies of scale in using third party vendors.
• The impact of globalisation on product supply and the value of having plant-level contacts and communications.

Carl has almost three decades of experience in the pharmaceutical sector. A biologist by trade, he worked his way up the ranks at Abbot for 12 years in operations. He then made his way into planning and supply chain operations during 11 years with Hospira (became Pfizer). He has spent the rest of his career at Mayne Pharma helping the Australian-headquartered pharma company manage its complicated clinical and commercial global supply chain.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

What next for trade events?

In this special events-themed episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with:

• Samuel Thangiah, co-founder of Life Science Integrates
• Tara Dougal, Head Of Content & Insights for Pharma at Informa Markets
• Edward McNamara, Vice President of Innovation Banking - Life Sciences at Cambridge Trust and the Co-Founder of BioXchange

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology event scene with his three guests, covering:

• The impact on event organisers and the pivot required over the last 18 months including the birth of the smart/hybrid event model.
• The side effect benefits of virtual events including international reach and even better speakers.
• A look forward to what local, regional, national and international trade events may look like in the future. And, how you and your organisation should be thinking about, approaching and planning for events in 2022.

Samuel is Co-Founder and Executive Director of Life Science Integrates. Life Science Integrates produces the debate-led events shaping conversations in Pharma, BioTech and MedTech.

Tara is Head of Content and Insights for the Pharma Portfolio at Informa Markets, where she has worked since 2015. In this role, Tara leads the digital and live content strategy for CPhI Worldwide, Pharmapack Europe and CPhI North America.

Ed is Vice President of Innovation Banking at Cambridge Trust and has both a life sciences and banking background. Prior to joining Cambridge Trust, Ed worked on business development for Biotech Vendor Services. Ed also co-founded a very successful networking group, BioXchange

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

The life science dating agent

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Martino Picardo, Chairman at Discovery Park.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Martino, covering:

• His ‘three careers’ over the last few decades, mainly spent translating science into commercial entities that make a difference.
• Building Stevenage Bioscience Catalyst from the ground-up from the middle of the golden triangle through relationships, partnerships and networking.
• The ‘holy trilogy’ of building incubators from a blank sheet to successful, thriving communities.
• Creating a life science village from a transitioning Pfizer R&D site in the UK into an ecosystem with 160 companies.
• Never being a better time to work in life sciences and for entrepreneurs to thrive in the ecosystem.

Martino is Chairman of Discovery Park and an Independent Consultant. With a a PhD in Biochemistry, Martino spent almost a decade with Amersham International after his time in academia.

He was the first CEO of the Stevenage Bioscience

Catalyst an ambitious concept to develop an Incubator and Accelerator, which is now as world class Science Park.

A former Entrepreneur in Residence at UMIP, Manchester and with the NHS, Martino is also on Board of BIONOW, and is Chairman of VisusNano Ltd and Evidential Ltd.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

A little, big announcement...

After years of frustration with recruitment service providers in our space and seeing many of my CRO/CDMO connections miss their growth targets because their talent agenda just can’t keep up, I decided to create a talent sourcing solution for pharma & bio outsourcing. Proudly introducing, Lead Candidate.

The business has been founded purely to support ambitious, growing CROs, CDMOs and pharma service firms. Lead Candidate aims to help address many of the common issues we see guests talk about - attracting people into industry, improving diversity in our sector and simply being better prepared for growth.

For many years, I strongly believed there was a need for long-term, responsible, talent acquisition from people who genuinely understand the intricacies of our industry. And a firm that would also take responsibility for championing careers and treating people with respect. 

Whether you’re looking to build your team or find your next move, visit Lead Candidate and get in touch with the team.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

The CDMO start-up... with a heck of a track record

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug product and sterile injectables sector with Cory Lewis CEO and President, Founder at INCOG BioPharma Services.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Cory, covering:

• The incredible 10-year journey of Cook Pharmica from a burning cash turnaround challenge to a $950M acquisition by Catalent.
• Customer-centric lessons learned from the franchise business model that’s being adopted by a CDMO start-up.
• The continued growth of the sterile manufacturing space in North America and several growth drivers.
• Life as a founder of a CDMO start-up after 25+ years as a senior industry exec.

Cory has spent 25 years in the CDMO space. After a spell with Baxter, he served as vice president of business development and marketing for Cook Pharmica until its 2017 sale to Catalent for $950M. He has since founded INCOG, a start-up CDMO that is investing $60M to build its 90,000 square foot headquarters in Fishers, Indiana and hiring about 150 people by the end of 2024.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

From Big Pharma to CDMO leader

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Dr. Louise Duffy, Ph.D., SVP and Head of the Scientific Project Leaders at Abzena.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Louise, covering:

• Learnings for CDMOs after almost three decades spent with big pharma. 
• How to balance the juggling act between dealing with hundreds of projects, clients, and systems as a fast-growing large molecule CDMO.
• Why the speed of innovation has massively increased in pharma and biopharma over the last 10 years.
• Tips on how to improve your presence and move forward quicker as a female leader.
• The importance of closer-knit supply chains involving originators, CDMO, technology, equipment, and material providers in developing increasingly complex molecules.
• The trend towards customised molecules with exquisite targeting and greater government interest as consequence of Covid.

Dr. Louise Duffy is a Senior Executive with an extensive background in the global bio/pharmaceutical industry with experience in business development, strategy, R&D, operations, and supply chain. She has more than 30 years’ experience in the industry, including increasing responsibilities at GlaxoSmithKline and Janssen. With broad CMC and regulatory experience and specialist knowledge in personalised medicine, biochemical engineering, chemistry, and biological sciences Louise is SVP and Head of the Scientific Project Leaders at Abzena.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

The change optimist

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Sébastien Ribault, Vice President & Head of End to End CDMO Services, Process Solutions at Merck Life Science.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Sébastien, covering:

• The ever-changing world of biotech and how things talked about 20 years ago are now becoming a reality for many treatments. 
• Re-inventing the drug development process when faced with the 'Everest' of taking a covid treatment from bench to production in just nine months. 
• Learning to ask those around you: "If you could do things differently - what would you do?" as a way of unlocking innovation and challenging the norm.
• The wave of personalised medicines and treatments on the horizon and the need to develop the tools to bring down costs and make them more accessible.

With a PHD in Molecular & Cellular Biology, Sébastien has been in the biotech space for almost 25 years. He has spent the bulk of his career at Merck Life Science where he has progressed to the position of Head of End to End CDMO Services for Process Solutions.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! 

Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile, and generate leads in life sciences.

 

The Public Health vaccine specialist

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Vanessa Elharrar  PPD, VP, Vaccines Business Strategy Lead, at PPD Vaccine Clinical Development and Medical Affairs.  

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Vanessa, covering:  

• Being at the centre of vaccine development and patient distribution over the last year. And the global pandemic’s role as a day of reckoning for the sector to do things differently in terms of virtualisation of trials becoming the norm.
• How MRNA vaccines could be the key to helping in HIV research and supporting patients at risk of AIDS.
• Carving a career path aimed at making the biggest impact on the global patient population.
• The need to be better prepared for future pandemics in terms of better better disease surveillance and detection, but also stockpiling vital equipment and having local vaccine manufacturing capability.
• The increasing trend towards CDMOs and CROs merging to offer a complementary and unified offering to help clients reduce timelines.

An MD/Doctor by trade, Vanessa now leads early engagement with Vaccine sponsors and offers strategic guidance in the development and implementation of vaccine trials. Her areas of expertise include COVID-19 vaccine development and medical monitoring of vaccine studies and HIV biomedical prevention. She is Board Certified in Preventive Medicine and Public Health having completed a Masters in Public Health at The John Hopkins University. If that was not impressive enough, Vanessa is also fluent in French, Spanish and Hebrew.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.